/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today.
In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients
Ciltacabtagene autoleucel (cilta-cel), Janssen's first cell therapy, is a structurally differentiated CAR-T with two BCMA-targeting single domain antibodies The Janssen Pharmaceutical Companies of Johnson